ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by retiredcopon Mar 23, 2021 5:14pm

271 Views

Post# 32860447

These guys invested with debentures

This was the first time we have had this type of investment and it was completely new to me. Thnaks to another investor who provided me with this article, that gives a good explaination how debentures playout ..

https://www.investopedia.com/terms/c/convertibledebenture.asp#:~:text=A%20convertible%20debenture%20is%20a,collateral%20backing%20up%20the%20debt

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide